Industry-standard equipment for high-accuracy genetic analysis and laboratory automation.
High-Throughput Screening (HTS) has transitioned from a specialized drug discovery tool to the backbone of modern clinical diagnostics and public health management. As global healthcare systems face increasing pressure to provide rapid, accurate, and cost-effective testing, the demand for CE Certified High-Throughput Screening Systems from reliable factories and exporters has reached an all-time high.
At its core, HTS leverages robotics, data processing software, liquid handling devices, and sensitive detectors to conduct millions of chemical, genetic, or pharmacological tests in a fraction of the time required by traditional methods. This technology is critical for identifying active compounds, antibodies, or genes which modulate a particular biomolecular pathway.
Process thousands of samples simultaneously, reducing laboratory turnaround time (TAT) by up to 80% compared to manual processing.
Minimized human intervention leads to higher repeatability and lower error rates in molecular diagnostic workflows.
Optimization of reagents and consumables per test significantly lowers the total cost of ownership (TCO) for clinical laboratories.
Shenzhen, often referred to as the "Silicon Valley of Hardware," has emerged as a global leader in medical device manufacturing. Companies like Shenzhen BioX Medical Co., Ltd. leverage a unique ecosystem that combines advanced R&D with a highly efficient supply chain.
Choosing a Chinese exporter for High-Throughput systems doesn't just mean cost savings; it means accessing the fastest iteration cycles in the industry. While Western manufacturers might take years for a hardware update, Chinese factories implement continuous "incremental innovation," integrating the latest AI chips and sensor technology into their CE-certified systems at a rapid pace.
For global procurement officers, CE Certification is the baseline for reliability and safety. In the context of High-Throughput Screening Systems, compliance goes beyond a simple label. It involves rigorous adherence to ISO 13485 (Medical Devices Quality Management Systems) and the transition to IVDR (In Vitro Diagnostic Regulation) in the European market.
Shenzhen BioX Medical ensures that every system exported undergoes a multi-stage quality control process:
Software and hardware validation protocols that meet international cybersecurity and data privacy standards (GDPR-ready).
Strict auditing of tier-1 suppliers to ensure consistent performance of optical sensors and robotic actuators.
Providing multi-language interfaces and localized technical support teams in Europe, North America, and the Middle East.
The industry is moving toward "HTS 2.0," where automation meets Artificial Intelligence. We are seeing several key trends that will define the next decade of laboratory medicine:
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
The company's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
Supported by a multidisciplinary team of engineers, laboratory specialists, and quality management professionals, the company continuously invests in innovation and product development. Comprehensive quality control procedures are implemented throughout design, manufacturing, testing, and inspection processes to ensure consistent performance and compliance with international industry standards.
Shenzhen BioX Medical Co., Ltd. serves customers across Europe, North America, Asia-Pacific, the Middle East, Latin America, and Africa. The company also provides flexible OEM and ODM services for distributors, diagnostic companies, and healthcare organizations seeking customized molecular testing solutions.
Our systems are CE certified and manufactured under ISO 13485 standards. We are also in the process of aligning all our molecular diagnostic platforms with the new EU IVDR requirements to ensure long-term compliance for our European partners.
Yes, BioX Medical provides comprehensive OEM and ODM solutions. This includes hardware customization, private labeling, software interface localization, and specific reagent integration to meet local market demands.
We offer a tiered support system: 24/7 remote diagnostics via cloud connection, localized training for distributor engineers, and a global spare parts logistics network to minimize downtime.
Depending on the system complexity and customization, our standard lead time is 4-8 weeks. Our 9,000 sqm facility allows us to handle high-volume orders without compromising quality.
Absolutely. Our HTS systems are designed with HL7 protocol compatibility, ensuring seamless data integration with most global hospital and laboratory information management systems.
Advanced diagnostic and laboratory tools for diverse professional applications.
BioX Medical
